In Brief: Pfizer
This article was originally published in The Gray Sheet
Executive Summary
Pfizer: Names P. Nigel Gray president of Pfizer's Hospital Products Group, effective July 1. Gray, who has been executive VP of the $1.15 bil. a year Hospital Products Group and president of its Medical Devices Division since 1993, takes over the Hospital Products president post from Henry McKinnell, who remains Pfizer executive VP and chief financial officer. Gray will continue to report to McKinnell. The management changes follow the decision of David Fitzgerald, another Hospital Products exec VP who also serves as president of its Howmedica division, to retire effective Dec. 31. The Hospital Products Group exec VP slots are not being filled, and a successor for Howmedica president has not yet been named. Valleylab President George Stewart succeeds Gray as president of the Medical Devices Division. Valleylab VP John Scibelli, PhD, becomes Valleylab president...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.